

II. REMARKS

The foregoing amendments are made to amend the claims. Support of the amendments to the claims can be found throughout the specification, for example, on page 17, line 15 through page 18, line 18. Substantive examination of the newly-presented claims is respectfully requested. If the Examiner notes any further matters which the Examiner believes may be expedited by a telephone interview, the Examiner is requested to contact the undersigned.

Respectfully submitted,

Date:

July 1, 2002

By:

Dahna S. Pasternak

Dahna S. Pasternak

Registration No. 41,411

ROBINS & PASTERNAK LLP
545 Middlefield Road, Suite 180
Menlo Park, CA 94025
Telephone: (650) 325-7812
Facsimile: (650) 325-7823

Version Showing Changes Made to Claims

Claims 1 through 20, canceled.

21. (New) A method of delivering rAAV to the brain of a subject suffering from a CNS disorder, comprising:

(a) providing a pharmaceutical composition comprising rAAV, said rAAV encoding a therapeutic protein; and

(b) administering said composition to the brain of the subject such that widespread distribution of said rAAV is achieved and the therapeutic protein is expressed at levels that provide a therapeutic effect in said subject.

22. The method of claim 21, wherein said rAAV is administered using convection enhanced delivery.

23. The method of claim 22, wherein said convection enhanced delivery is performed using an infusion pump.

24. The method of claim 22, wherein said convection enhanced delivery is performed using an osmotic pump.

25. The method of claim 21, wherein said rAAV is administered to the striatum.